FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

07 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

22 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 8 2023 16:53:28 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023

03 8 2023 07:01:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Chief Financial Officer

03 8 2023 06:55:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET

27 7 2023 07:00:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology

10 7 2023 07:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 7 2023 17:30:31 提供 Nasdaq GlobeNewswire

Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)

20 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 6 2023 16:54:20 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023

15 5 2023 07:05:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer

15 5 2023 07:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET

08 5 2023 16:05:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 5 2023 18:06:50 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 4 2023 17:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces CFO Resignation

05 4 2023 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 3 2023 17:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

09 3 2023 07:00:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET

06 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease

24 2 2023 08:00:00 提供 Nasdaq GlobeNewswire